Global Health & Biotech Archives | Page 65 of 292 | Be Korea-savvy

Archive by category Global Health & Biotech

Best-in-class Just Got Better; Smith+Nephew Announces 510(k) Clearance of New CATALYSTEM™ Primary Hip System

Best-in-class Just Got Better; Smith+Nephew Announces 510(k) Clearance of New CATALYSTEM™ Primary Hip System

Engineered for precision, confidence and efficiency in surgery – and compatible with the CORI◊ Surgical System Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the United States Food and Drug Administration. The system is designed to address the evolving demands of [...]

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine

WASHINGTON, July 15, 2024 (Korea Bizwire) – Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine against Sudan ebolavirus, with healthy volunteers receiving the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Uganda. There are currently no approved vaccines for this strain of ebolavirus, which saw an outbreak end just last year. [...]

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will [...]

New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia Research and Treatment

New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia Research and Treatment

BOSTON, Jul. 11 (Korea Bizwire) — Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has today released a significant research report entitled Chronic Lymphocytic Leukemia (CLL) – Global Clinical Trial Landscape. This expert monthly report, provided by the [...]

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

VANCOUVER, British Columbia, July 11, 2024 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its second quarter 2024 financial results after market close on August 1, 2024. Following the [...]

FSH-free versus FSH-primed Infertility Treatment of Women with Polycystic Ovary Syndrome using Biphasic in Vitro Maturation: a Randomized Clinical Trial

FSH-free versus FSH-primed Infertility Treatment of Women with Polycystic Ovary Syndrome using Biphasic in Vitro Maturation: a Randomized Clinical Trial

AMSTERDAM, July 10, 2024 (Korea Bizwire) – This randomized, controlled trial was conducted at a tertiary IVF center, Ho Chi Minh City, Vietnam. Between January 2023 and June 2023, 120 women were randomized. Eligible women were aged 18–37 years with polycystic ovarian syndrome (PCOS). After providing written informed consent, participants were randomized (1:1) to undergo [...]

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

SPRING, Texas, Jul. 9 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally [...]

MedPro International Sponsors Medical Services to Over 300 Patients

MedPro International Sponsors Medical Services to Over 300 Patients

SUNRISE, Florida, USA, July 09, 2024 (Korea Bizwire) – MedPro International, through its philanthropic Global Giving program, sponsored medical services to more than 300 patients at a one-day event in Loma in Biñan City, Philippines. Held at a local medical center, the event provided comprehensive care, including vital screenings, cardiac EKG tests, x-rays, urine analyses, and doctor [...]

Smith+Nephew is Trailblazing a New Path for Female Surgeons with its Orthopaedics for All Initiative; a First-of-its-kind Global Advisory Board

Smith+Nephew is Trailblazing a New Path for Female Surgeons with its Orthopaedics for All Initiative; a First-of-its-kind Global Advisory Board

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announces its Orthopaedics for All initiative – a global advisory board established to amplify diversity by building equity, breaking biases, and inspiring inclusion for individuals wishing to pursue a career in orthopaedic surgery. The disparity of women in the field of orthopaedic surgery compared to men is staggering. According [...]

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

SPRING, Texas, Jul. 8 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done in breast, lung, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of retinoic acid nuclear receptor gamma which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]